SCHEMBL2345220

SCHEMBL2345220

COc1ccc(NC(=O)c2cccc3c2OCCN3c2ncccc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
TOP1 P11387 2/20 0.51
MAPT P10636 6/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
GAA P10253 2/20 0.48
RAB9A P51151 3/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
POLB P06746 3/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MT-CO2 P00403 1/20 0.44
PTGS2 P35354 1/20 0.44
PPARG P37231 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1548738 0.92 KDM4E (0.50) L3MBTL1MAPTMEN1KMT2AGAA
SCHEMBL2346333 0.91 L3MBTL1 (0.44) L3MBTL1TOP1MAPTMEN1KMT2A
SCHEMBL14540807 0.91 L3MBTL1 (0.43) L3MBTL1TOP1MAPTALDH1A1POLB
SCHEMBL2345110 0.90 EGLN1 (0.43) L3MBTL1TOP1MAPTMEN1KMT2A
SCHEMBL2345187 0.90 KDM4E (0.49) L3MBTL1MAPTRAB9AALDH1A1NPC1
SCHEMBL2346049 0.90 TRPV1 (0.52) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL2341748 0.90 L3MBTL1 (0.43) L3MBTL1TOP1MAPTMEN1KMT2A
SCHEMBL2349154 0.89 P2RY1 (0.47) L3MBTL1MAPTKMT2ARAB9ANPC1
SCHEMBL2349235 0.88 TRPV1 (0.43) RAB9AALDH1A1NPC1SMN1; SMN2TP53
SCHEMBL1549275 0.88 TRPV1 (0.43) L3MBTL1MAPTALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2314585-B1 Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC (JP) 2012-09-12 EP claimed
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY JAPAN TOBACCO INC. (JP) 2006-02-16 US claimed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY JAPAN TOBACCO INC. (JP) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY TRPV1, TRPV2, TRPA1 L3MBTL1 3518/4885TOP1 3500/4885MAPT 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.